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A  given individual once infected with a  Group A  streptococcus of any sero- 
logical type rarely is reinfected with an organism of the same type. Presumably 
the low incidence of reinfection is due to type-specific immunity correlated with 
the persistence  of type-specific antibodies.  The duration of this irnrnlxnity fol- 
lowing  a  streptococcal  infection  has  not  been  established.  An  approach  for 
obtaining laboratory evidence for the duration of immunity is the study of the 
persistence  of type-specific antibodies  which  are  usually  demonstrable in pa- 
tients following streptococcal infections. It has been shown by others that type- 
specific antibodies in some individuals persist for as long as 3 years (1-6). There 
are few data available covering longer periods of time. 
In this  study  immunological  and  clinical  data  are  reported  on individuals 
who had  streptococcal infections as  long ago as 32 years.  Many of the indi- 
viduals  had  experienced  their  streptococcal  infections  before  sulfonamide  or 
penicillin therapy was available, which is of importance because of the possible 
effect of therapy on antibody response (5,  7). The causative streptococci were 
isolated  and  typed  at  the  time  of the  infection,  and  the  cultures  frozen and 
dried.  Type-specific  antibodies  were  demonstrated  by means  of  bactericidal 
tests and, in a  few instances,  confirmed by mouse protection tests. 
Materials and Methods 
1. Bactericidal Test.--The presence of type-specific antibodies in human blood was estab- 
lished by one or more of the following methods. 
(a) Direct Tests.--When  fresh heparinized  blood could be obtained at a time suitable for 
testing, the direct bactericidal test was performed by the technique previously described (8, 9). 
Results are frequently better with this method than with the indirect method described in the 
next paragraph since use of serum and blood from two different individuals is avoided. Errors 
due to slight incompatibility  between serum and blood ceils or to the undiscovered presence 
of streptococcal antibodies in the "normal" individual supplying the whole blood necessary to 
furnish phagocytic  cells are thus avoided. The elimination  of this  source of error  by using 
washed leucocytes has other obvious inherent errors, and was impracticable. 
(b) Indirect Tests.--In the indirect test, serum or plasma is tested for the presence of anti- 
bodies which promote phagocytosis of streptococci by human phagocytes from another donor. 
Usually 0.2 ec. or 0.05 cc. of test plasma or serum was used, suitably controlled with plasma or 
serum taken at approximately the same date from normal individuals. Serial dilutions of cul- 
ture in 0.05 cc. or 0.1 cc. volume and 0.3 ce. of fresh heparinized normal human blood were 
271 272  PERSISTENCE  OF  TYPE-SPECIFIC STREPTOCOCCAL ANTIBODIES 
employed as previously described (8, 9). Blood was considered normal for the purposes of the 
test if it did not contain demonstrable antibodies for the serological types of streptococci 
included in the experiment. 
(c) Replacement of Plasma in Normal  Blood by Plasma  To Be Tested.--Occasionally the 
plasma of normal human blood was replaced by the test plasma, and the experiment then 
carried out in the same way as a direct test, using the mixture of normal blood cells and test 
plasma instead of whole untreated Mood. It was found that this procedure had little, if any, 
advantage over the simpler method of merely adding a fixed amount of plasma to the whole 
normal Mood. Due regard to compatibility of Mood groups was observed by using Group 0 
blood when blood of matching group was not available. 
2. Passive Protection Tests in Mice.--In some instances the finding of type-specific anti- 
bodies by means of bactericidal tests was confirmed by passive mouse protection tests either 
with untreated serum or with gamma globulin concentrated  by precipitation  with sodium 
sulfate. Details are included with each experiment. 
3. Collection of Blood.--Abbott's  heparin sodium solution containing 1000 units/cc. (ap- 
proximately 10 mg./cc.) was used: 0.1 cc. for 20 cc. of human blood. When blood was left over 
from direct tests, plasma was removed from the cells at the end of the day for further  tests 
by the indirect method. 
Blood for serum was collected in the usual way by venipuncture. Whenever practicable the 
blood was allowed to clot and retract  in vaseline-lined tubes without  rimming, in order to 
prevent hemolysis. 
4. Streptococcal Cultures.--Many of the strains isolated from the patients at the time of 
their infections were preserved in our frozen and dried stock, and are still available. These 
cultures together with others of the same and heterologous types were used for testing. With 
the exception of cases 4, 21, and 23, all strains were typed in this laboratory. Most of them 
were identified at the time of the infection; others were typed later with sera not available 
earlier. The types of all available strains were checked at the beginning of these experiments 
EXPERIMENTAL 
Persistence of Type-Specific Streptococcal Antibodies in Man.--In  Tables I  a, 
I  b, and I  c,  a  record of the antibodies found in individuals selected for this 
study is presented.  1 Many of these persons were employees of this institution 
or were patients in the various departments of The Rockefeller Hospital. In 
half of the known infections, most of which occurred 15 to 32 years ago, before 
chemotherapeutic  drugs  were  generally  available,  type-specific  antibodies 
corresponding to the type known to have caused the infection were found. In 
the others with known infections, some of whom had been treated with snifon- 
amides or penicillin, type-specific antibodies were not demonstrable or were too 
weak to assess with certainty in current tests. 
Tables I  a and I  b show the results after known infections. In addition to the 
findings  on the presence or absence of antibody to strains of the homologous types 
associated with the preceding infection, data on the positive and negative reac- 
tions with strains of heterologons types axe also included. Usually a number of 
strains of each type was tested and the experiments repeated several times. 
t The cooperation of all  these individuals who have  so generously supplied me, often 
repeatedly, with samples of their blood is greatly appreciated. R.  C.  LANCEFIELD  273 
In  12  individuals  type-specific antibodies  against  11  different  homologous 
types following 14 separate infections persisted for 4 to 32 years (Types 2, 3, 
6, 12, 13, 14, 15, 18, 22, 26, and 28) (Table I  a). In 13 individuals, on the other 
hand, who also had had known infections 1 to 31 years previously (Table I  b), 
no type-specific antibodies  were demonstrable  against  14 different types fol- 
lowing 17 different infections (Types 1, 3, 8, 12, 15, 17, 18, 19, 23, 25, 36, 48, and 
strains  H105 and  1RS85).  In 3  of these individuals  homologous type-specific 
antibodies,  which had  been present  shortly  after the infection  (cases  14,  18, 
and  23),  had  disappeared  at  the  time  when  these individuals  were retested 
(footnote to Table I b). In 12 other individuals, although the strains causing the 
infections  were not available,  type-specific antibodies were observed. In some 
of  these  individuals  no  history  of  streptococcal  infections  was  obtained, in 
others scarlet fever or severe pharyngitis  was known to have occurred. Many 
in this group had antibodies against several types. Antibodies in various com- 
binations were found against the following: Types 2, 3, 6, 8, 12, 13, 15, 19, 36, 
43, and Strains B514, C36, and B393. One individual,  case 30 (Table I  b), had 
demonstrable antibodies against  7 specific types or strains,  although none re- 
suiting  from  the  only known  preceding  infection. 
In one patient  multiple infections with different types were observed, case 
10 (Table I  c). The persistence of antibodies in this individual was not related 
to the severity of infection. Following 3 of the 5 infections, antibodies persisted 
for many years, whereas in the other two, none was demonstrable. In addition, 
in the absence of any known infections, antibodies to two other types were also 
present. 
In the  course of this  study in some individuals  no type-specific antibodies 
were demonstrated.  These individuals were only tested against a limited num- 
ber of strains,  and  type-specific antibodies  might  have been demonstrable  if 
more types had been included. 
These observations are  not sufficiently extensive to draw conclusions as to 
the prevalence  of streptococcal types. They are recorded to show that strew 
tococcal  antibodies  are  frequently  present  in  normal  adults  and  persist  for 
many years. 
Examination of the data and of the clinical records of the individuals studied 
gave  no  suggestion  that  the  persistence  of  type-specific  antibodies  was 
correlated with the severity of the infection or with the serological type of the 
homologous streptococcus. This is in contrast to the findings of others that the 
initiation of type-specific antibody response is closely correlated with the failure 
to eradicate streptococci from the throats of patients (5, 7). The interval since 
the infection occurred was,  however, found to be of some importance  in the 
present study of persistence of type-specific antibodies. In the few instances in 
which data were available on this point, there was some evidence of a gradual 
decline in titer with time (cases 9, 10, 18, and 23). This finding is in agreement TABLE I  a 
Type-Sl)~ifw  Antibodies  in  Human  Sera  Following  Infections  witk Group A  Streptococci  of 
Known Types 
(a)  Presence as demonstrated in current bactericidal tests. 
Case  Streptococcal 
infection: 
No.  serolgical  type 
1  Type 14 
2  "  26 
3  "  3 
4  "  13 
5  "  12 
6  "  15 
7  "  22 
Strain D215:~ 
8  Type 22 
"  41 
9§  "  26 
lOll  "  2 
"  6 
"  28 
12  "  6¶ 
13  "  18¶ 
Interval 
since  in- 
fection 
yrs. 
32 
22 
21 
22 
32 
21 
21 
19 
15 
6 
15 
22 
17 
1 
4 
9 
Homologous type- 
specific antibodies 
Present 
Type 14 (+++) 
"  26 (+++) 
"  3 (++) 
"  13 (++) 
"  12 (4) 
"  15 (++) 
"  22 (+++) 
Heterologous type-specific  antibodies 
Present 
Type 3 (+++) 
Type  3  (4-) 
"  48 (4)* 
Type 12 (÷÷) 
"  8  (+q-) 
Absent 
Types ~ted 
1, 3, 6, 18, 19, 26 
i 
I, 6, 14, 18, 19 
i  1, 6,  14, 19, 22, 26 
2, 6, 18, 22, 28, 49 
1, 3, 26 
22, 49 
1, 4,  15,  6 
Not tested, 
strain lost 
Type 22 (+÷÷) 
Not tested, no 
serum 
Type 26 (÷÷÷) 
"  2  (+) 
"  6 (+++) 
"  28 (÷÷÷) 
"  28 (-4-) 
"  6 (4++) 
"  18 (4+++) 
i 
4 
None tested 
Type 13 (÷) 
"  15 (++) 
Type  2  (+) 
Type 12  (++) 
gc 
1, 4,  11, 12,  14,  17 
18, 19, 22, 23, 26, 
27, 36, 38, 40, 41, 
43, 44, 48, 49 
i  1950:  4,  5,  14,  22 
24 
i  1951:  1, 5, 14, 24 
] 1956:  4,  5,  13,  48 
49** 
22 
19 (+++) 
In all tables 4- to ÷÷÷÷  indicates estimate of strength of reactions. 
* Known cross-relationship between Types 13 and 48 (8). 
This strain, isolated at the time of the infection, could not be typed with the available 
sera.  It has since been lost. 
§ Serial bleedings were still available from case 9  (a patient in the rheumatic fever series) 
dating from 1949,  7 years after her infection in  1942, to the present.  When tested in  1957 
these showed a  gradual decline in titer, but her blood still contained readily demonstrable 
antibodies. 
Tests on her serum were made by Dr. Rothbard at the time of her infection with strain 
Cl18 (see Tables I, II, IV, and V of his paper (2)). These earlier sera had been used up so 
that none before 1949 was available for the current tests. 
[I See also Tables I  b and I  ¢. 
¶  In this infection the patient was treated with penicillin. 
** Dr. Floyd Denny kindly furnished records of tests on this patient which he made in 
1950 and  1951. Type 6 was also positive in his tests, as well as in the current tests done in 
this laboratory in 1956. 
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Type-Specific  Antibodies  in  Human  Sera  Following Infections  arith  Group  A  Streptococci  of 
Known Types 
(b) Absence as demonstrated in current bactericidal tests. 
Case  Stre:ptococcul in-  Interval since  Occurrence of homologous  Heterologou.s tyI~e-specific 
No.  fect]on: serologi-  infection  type-specific antibodies  antibodies absent 
cal type 
Tyhes tes~e.d 
10"  See Table I a 
14 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
30¶ 
Type 8 
"  3~ 
Type 125 
Strain 
22 yrs. 
20  " 
1  ¢¢ 
3~  " 
9-22 wks. 
None present 
Type 12 (+q-q-+) 
None present 
Strain  1RS8S  (++)§ 
6, 28 
1942:  6, 28§ 
1RSSS~; 
Type 23 
"  36 
"  1 
"  25 
"  36 
"  17:1: 
"  48 
"  3~t 
"  15 
"  1 
"  19 
"  18 
Strain H105:~ 
2 yrs. 
14  " 
27 yrs. 
23  " 
31  " 
20  " 
6  mos. 
17 yrs. 
12 yrs. 
1  " 
14  " 
18  " 
16  " 
11  " 
I0  " 
1  yr. 
None present§ 
None present 
Type 36 (+-[-)[I 
None present 
None present 
¢¢  ¢¢ 
g¢  ¢¢ 
¢¢  ¢¢ 
¢¢  ¢¢ 
[¢  eg 
1944: 6, 28§ 
1955:28 
None tested 
28 
2 
8, 36 
None tested 
None tested 
1956: 2,  13, 28, 44 
None tested 
3,  18,  19, 26 
1, 3, 4, 12, 14, 15, 17, 18, 
19, 22, 23, 27, 28, 38, 
48, 49, strain B514 
* See also Tables I a and I c. 
In this infection the patient was treated with sulfonamides or penicillin. 
§ Tested 1942 and 1944 by Dr. S. Rothbard. 
II Tested 1942 by Dr. A. G. Kuttner (case 15 in reference 1). I am indebted to Dr. Rothbard 
and Dr. Kuttner for their records, and to Dr. Harrison F. Wood for supplying me with current 
serum from case 23. 
Case 30 had antibodies without history of known infections for the following types: Type 
2  (-k), Type 6  (-k-l-q-), Type  13  (+-F), Type 36 (-F-I--I-), Type 43  (q--/--b), strain C36 
(+q-q-), strain B593 (+q-q-). 
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TABLE I c 
Type-Specific Antibodies in Human Serum Following  Infections with Group  A  Streptococci  of 
Known Types 
(c)  Variable occurrence after  multiple infections in one individual as demonstrated in 
current bactericidal tests. 
Streptococcal infectior 
Case I0 
Clin/cal findings 
Severe pharyngitis 
Superficial  infection  of 
finger 
Severe  pharyngitis  and 
facial erysipelas* 
Moderate pharyngitis 
Occurrence of type- 
specific antibodies 
Type 2 (+) 
None present 
Type 6 (+q--b) 
"  28 (-[-+-[-) 
....  (++) 
"  "  t:l:) 
Preceding infection unk  Type 13 (+) 
"  ....  15 (++) 
Heterologous type- 
specific antibodies 
absent 
Types tested 
1, 4,  11,  12,  14,  17, 
18,  19, 22, 23, 26, 
27, 36, 38, 40, 41, 
43, 44, 48, 49, and 
numerous  uric]as- 
sifted strains 
* In this infection the patient was treated with sulfanilamide. 
with the findings of others (1, 2, 4, 5). On the other hand, several of the strongest 
reactions were obtained in individuals studied 15 to 32 years postinfection. 
Two of the most severe infections resulted from cuts on the hand followed by 
heavy accidental inoculation of streptococci. Homologous type-specific anti- 
bodies were readily demonstrated  22 years later in one of these individuals 
(case 2). None was found, however, in current tests with the serum of the other 
individual (case 19), who had had a severe infection 27 years earlier. In another 
severe case  (case  1),  the  patient was  hospitalized for several weeks  with  a 
peritonsillar abscess. He still has good antibody after 32 years, while in case 10 
with a severe Type 3 infection, the individual after 20 years has no demonstrable 
Type 3  antibody. 
The persistence of antibody response to any given streptococcal infection was, 
therefore, entirely unpredictable: long persisting antibodies in some instances 
followed clinically mild infections, whereas severe infections might produce no 
response, or only one of low titer. 
The serum of case 5 in current bactericidal tests showed weak, but definite TABLE  II 
Examples  of Tests for  Type-Specific Antibodies in Human  Sera  Demonstrable  Many  Years 
after Known Infections with Group A  Streptococci 
Direct or Indirect Bactericidal Tests 
Strains tested  Conditions of test* 
No. of streptococci inoc- 
ulated 
No.  of  streptococci  at 
end  of  test  with 
human  serum  or 
plasma from: 
Case  1 
"  2 
"  3 
"  30 
Results  of test 
rypel4 
Strain 
$23/101 
FIomologous 
to case 1 
No.  of  streptococci  inoc- 
ulated 
No.  of streptococci at 
end  of  test  with 
human  serum  or 
plasma from: 
Case  1 
"  2 
"  3 
u  30 
No. of  colonies 
Type 26 
Strain 
J17F/90 
Homologous 
to case 2 
Type 3 
Strain D121 
Homologous 
to case 3 
No. of streptococd inoc- 
ulated 
No.  of  streptococci  at 
end  of  test  with 
human  serum  or 
plasma from: 
Case  1 
"  2 
"  3 
"  30 
Inoculum 
Bo~idal  tests 
7  0 
o~  C 
¢IJ  ~J 
~iC 
I 
9 
700 
C 
1000 
Antibody found 
2  +++  Type 14 
350  No  "  " 
240  "  "  " 
188  "  "  " 
Inoculum 
i  I  i 
,  i 
oo  o~  225  200 
500  40  3  0 
~o  C  1000  i00 
C  100  47 
Inoc~um 
i101  1 50  23  13 
i 
Baaer/dda/tests 
C  C 
0  0 
24  0 
C  C 
C  i85 
0  0 
0  0 
500  340 
No  Type 26 
++%  "  . 
No  "  " 
No  Type3 
%+%  ,,  , 
No  "  " 
Interval 
since 
infection 
32 yrs. 
22 yrs. 
No 
known 
Type 
3in- 
fection 
21 yrs. 
The control, case 30, has antibodies to other types (infection unknown), Types 2, 6,  13, 
36, 43, strains C36, B593. 
* For direct tests, each tube contained: 
0.1 cc. culture dilution. 
0.3 cc. fresh heparinized blood. 
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TABLE II--(Conduded) 
For indirect tests, each tube contained either: 
(1)  0.2 cc. test plasma or serum. 
0.05 cc. culture dilution. 
0.3 cc. fresh heparinized normal blood. 
or (2)  0.05 cc. test plasma or serum. 
0.I cc. culture dilution. 
0.3 cc. fresh heparinized normal blood. 
At the end of 3 hours' rotation at 37°C., 0.1 cc. of each mixture was plated in blood agar 
pour plates for counts of surviving organisms. 
The culture dilutions were plated at the beginning of the test to determine the size of the 
inoculum. 
In all tables: 
~o  indicates  innumerable  colonies with  blood  completely hemolyzed. 
C indicates  confluent growth with some areas of unhemolyzed blood. 
2000 to 500 colonies were estimated by comparison. 
Colonies on plates  with  less than 400 were usually counted. 
In the strain designations, the figure preceding the slanted line is the strain number, and 
the figure following the slanted line indicates the number of mouse passages. 
For further details, see Methods. 
Type 12 antibody. This case was of special interest because the infection was 
followed by an  attack  of glomerulonephritis  in  1926.  The  strain  (K235)  ob- 
tained from Dr. W. T. Longcope in 1932, at that time could not be typed. When 
this culture was reexamined in 1958, no M  antigen was demonstrable by pre- 
cipitin reactions. The absence of M  antigen was confirmed by the failure of the 
strain to grow in rotated tubes containing normal human blood (8, 9). In spite 
of 129 serial mouse passages made in an attempt  to identify its type-specific 
component, no M  antigen was demonstrable.  The strain,  therefore,  could not 
be  typed  by  the  anti-M  precipitin  reaction.  However,  a  10  T  antigen  was 
identified by means of agglutination reactions. The 10 T  antigen has never been 
observed except in Type  12  strains.  Strain  K235,  therefore,  was classified  as 
probably  belonging  to  Type  12.  Dochez's widely used  strain,  N.Y.5,  has  a 
similar  antigenic  composition,  12  M  and  10 T,  as have several  other known 
strains isolated during this period  (10). 
In recent years, Type 12 has been frequently associated with acute glomer- 
ulonephritis. These strains, however, in contrast to strain K235, are character- 
ized by the antigenic composition 12 M, 12 T. Strains containing 12 M  and 10 T 
antigens  are extremely rare at the present  time. 
Examples  of Type-Specific  Bactericidal Reactions Demonstrable Many  Years 
after Streptococcal Infections  of Known Type.--As shown in Table II, the growth 
of Type 14 was specifically inhibited by the serum of case 1 obtained from an 
individual with a known infection due to this type which had occurred 32 years 
before. The sera of three other individuals failed to inhibit the growth of this 
strain. 1~.  C.  LANCEFIELD  279 
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The growth of Type 26 was specifically inhibited by the serum of case 2 ob- 
tained from an individual with a known infection 22 years before, due to this 
type. The sera of three other individuals failed to inhibit the growth of this 
strain. 
The growth of Type 3 was specifically inhibited by the serum of case 3 ob- 
tained from an individual who had had a known infection 21 years before, due 
to this type. This strain was also inhibited by the serum of case 2 obtained from 
an individual who had had no known infection with this type. In contrast to 
the sera obtained from cases 1, 2, and 3, that of case 30 had no demonstrable 
antibodies for the three types studied, although this individual had antibodies 
for 7 other types or strains (Table I b). 
Passive Protection Tests in Mice with Human Sera.--In a  previous paper a 
close  correlation between the  occurrence of protective antibodies  and  anti- 
bodies promoting phagocytosis in  bactericidal  tests  was  demonstrated  with 
rabbit immune sera (9). A  similar correlation has now also been shown with 
human  sera  whenever  these  "bactericidal"  antibodies  are  demonstrable  in 
moderate titer, irrespective of whether the antibodies resulted from a  known 
infection with the homologous type or appeared in the absence of such data on 
the preceding infection. 
In Table HI examples of these findings are given. In case 29 the serum con- 
tained Type 3  antibodies without bacteriological data on an infection of the 
individual with streptococci of this type. He had a history of scarlet fever in 
1927, but no throat cultures were taken. His serum, as well as the gamma globu- 
lin fraction separated from it by standard procedures of sodium sulfate pre- 
cipitation, protected mice against infection with Type 3 streptococci in doses 
of 10  -5 to 10  -~ cc. of culture. Further data not included in the table showed 
that half of the mice receiving 10  ~  cc. and 10  -4 cc. of culture also survived in 
these protection tests.  The serum or gamma globulin fraction from cases  10 
and 4 showed no significant protection against infection with Type 3 strepto- 
cocci. Cases  10 and 4, however, possessed antibodies for Types 6 and 13 re- 
spectively with which they were known to have been infected 17 and 22 years 
before. In passive protection experiments,  the  sera of these two individuals 
each protected  mice against  their homologous strains,  although not in high 
liter. The small amount of Type 13 antibody in case 10 serum, or the trace of 
Type 3 antibody in case 4 serum, detectable by bactericidal tests, was probably 
insufficient to give convincing evidence of passive protection in mg~e. 
Methods of Measuring Content of M Antigen in Group A  Streptococci.-- 
(a) Ability to Resist the Bactericidal Effect of Normal Human Blood in Bac- 
tericidal Tests.--In previous papers it was shown that the ability of Group A 
streptococci to produce M  antigen determines whether or not they can resist 
phagocytosis and  grow  in  normal  human blood in  bactericidal tests  (8,  9). R.  C.  LANCEFIELD  281 
These observations have now been extended by using this property as a rough 
quantitative measure of the M antigen produced by a strain. 
Phagocytosis, in the bactericidal system used, only occurs when the leuco- 
cytes are in constant contact with the streptococci (11). A comparison is made 
in Table IV a between duplicate sets of tubes containing normal human blood 
TABLE IV a 
Metkods of Measuring Conlent of M Antigen in Group A  Streptococci 
(a)  Ability to resist bactericidal effect of normal human  blood. 
Direct Baaericidal  Teas 
Strains tested 
Type 3 
Strain D58X/ll 
M  antigen +-}--t--4- 
Type 3 
Strain C203/42 
M antigen +++ 
Type 3 
Strain D121 
M antigen ++ 
Type 3 
Strain F208 
No M  antigen 
Conditions of test* 
No. of streptococci inoculated 
No. of streptococci at end of test with 
normal human blood 
(a) rotated tubes 
(b) stationary tubes 
No. of streptococci inoculated 
No. of streptococci  at end of test  with 
normal human blood 
(a) rotated  tubes 
(b) stationary  tubes 
No. of streptococci inoculated 
No. of streptococci at end of test with 
normal human blood 
(a) rotated tubes 
(b) stationary tubes 
No. of streptococci inoculated 
No. of streptococci at end of test with 
normal human blood 
(a) rotated tubes 
(b) stationary tubes 
Results of test 
No. of colonies 
Inoculum 
c  70o 
700 
Inoculum 
Bactericidal test 
Inoculura 
Bactericidal lest 
730  204  0 
700  500 
[);OC~gl~lgt, 
o  8,  I  ,4[ 
Bactericidal test 
6  0  0 
1000  175 
200 
146 
0 
201 
0 
66 
0 
50 
* Each tube in these tests contained 
0.1 cc. culture dilution. 
0.3 cc. fresh heparinized normal human blood. 
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and serial dilutions of culture in which one set is rotated during incubation and 
the other set is kept stationary. The amount of growth in the pairs of tubes is 
a reflection of the amount of M antigen produced. With maximal amounts of M 
antigen, the streptococci are protected from phagocytosis even in rotated tubes, 
and growth in the two sets of tubes is identical and is initiated by very small 
inocula. With strains containing no demonstrable M  antigen, the cultures in 
stationary tubes grow out normally from small inocula but in the rotated tubes 
even the cultures with large inocula are quickly sterilized. 
Since intermediate growth occurs in the rotated tubes when the precipitin 
tests show intermediate amounts of M antigen, this technique can yield valuable 
information as to the M-producing properties of strains. The extremes of maxi- 
mal M  and complete absence of M  have been illustrated in a preceding paper 
(9),  but in the present experiments, useful strains  were sought in the inter- 
mediate range. Table IV a shows the growth of different strains in rotated and 
stationary tubes compared with an estimate of M  antigen from the precipitin 
reaction. With strain D58X/ll which gave the best precipitin reactions, the 
two sets of tubes were indistinguishable in growth. Strains C203/42 and D121 
showed progressively less  growth in the rotated sets, and the M- strain (12), 
F208, only had 6 colonies left from the largest inoculum (rated oo in the  table). 
By means of this biological assay, therefore, as well as by M  precipitin re- 
actions, Strain F208 would be eliminated from any experiment requiring an 
M + strain (12). Strain D58X/ll would be used whenever maximal M  antigen 
is required; for example, in bactericidal tests of sera with high antibody content, 
or for virulence or immunization experiments. Strains C203/42 and D121, which 
show an intermediate amount of M  and growth in normal human blood, would 
be selected as test strains with human sera containing antibody in low concen- 
tration. 
(b)  Determination  of the Amount of Antibody Necessary to Inhibit Growth of 
Streptococci in Bactericidal Tests.--The best M + strain, D58X/ll (Table IV a), 
and an intermediate strain, D121, were tested against serial dilutions of Type 
3 rabbit antiserum. The results in Table IV b show that Strain D58X/ll  re- 
quires at least 4 or 5 times as much antibody as Strain D121 for equivalent in- 
hibition of growth in bactericidal tests: a 1:25 dilution of rabbit antiserum has 
essentially the same effect on strain D58X/ll as a 1:100 dilution has on strain 
D121. This indicates that Strain D58X/ll has more M antigen to combine with 
antiserum than is the case with Strain D121, a conclusion  in agreement with the 
results of comparing the growth of these strains in rotated and stationary tubes. 
In numerous  tests not included in  the  table, it was  observed that in  the 
stationary sets the presence of antibody had no effect on growth even of M + 
cultures,  the  growth  in  comparable  series  of  stationary  tubes  being  indis- 
tinguishable whether they contained normal or immune serum. In rotated tubes, 
on the other hand,  immune  sera markedly enhanced the  destruction of M + 
strains but had no more effect than normal serum on M- strains. R.  C.  LANCE]FIELD  283 
TABLE IV b 
Methods  of Measuring Content of M  Antigen in Group A  Str.ptococci 
(b) Amount of antibody necessary to inhibit growth in bactericidal tests. 
Indirect  Bactericidal  Tests 
Strains tested 
Type 3 
Strain D58X/ll 
M antigen +++4- 
Conditions of test* 
No. of streptococci inoculated 
No. of streptococci at end of test with 
Results o[ test 
No. of Colonies 
Inoculum 
B~l~r~al test 
Type 3 
Strain D121 
M antigen @ + 
normal  human  blood  and  rabbit 
serum: 
Type 3 anti-M serum  1:1 
"  "  "  i:  5 
"  "  '¢  1: 25 
"  "  "  1: 50 
"  "  "  1: i00 
"  "  "  1: 200 
Normal rabbit serum  1:1 
No. of streptococci inoculated 
No. of streptococci at end of test with 
1 
48 
212 
500 
C 
O~ 
normal  human  blood  and  rabbit 
serum: 
Type 3 anti-M serum  1:1 
"  "  "  1: 5 
"  "  "  1: 25 
"  "  "  1:50 
"  "  "  1:100 
"  "  "  1: 200 
Normal rabbit serum  I: 1 
0  0 
0  0 
20  2 
104  120 
C  250 
C  500 
C  500 
luoculum 
61  20  I  2 
I 
0  0  0 
3  0  0 
1  6  0 
83  8  4 
129  18  0 
500  31 
C  500 
* Each tube in these tests contained 
0.05 cc. dilution of rabbit serum. 
0.1 cc. culture dilution. 
0.3 cc. fresh heparinized normal human blood. 
For further details of tests, see Methods and Table II. 
The results of these tests show that Strain D58X/11 requires 4 to 5 times as much antibody 
as Strain D121  for equivalent inhibition of growth in bactericidal tests: e.g. the 1:25 serum 
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Optimal Proportions of M  Antigen  and Antibody  Required for Demonstrating 
Antibody  in Human Sera.--From these considerations  it is obvious that  for 
studying the content  of type-specific antibodies in human  sera,  which vary 
from high concentrations to barely discernible levels, the selection of a suitable 
strain for the assay is of first importance. Examples  of the  influence  of  this 
factor are shown in Table V. Four strains with varying ability to produce Type 
3 M  antigen were tested in serial  dilution against the blood of 3 individuals 
known to have circulating  Type 3 antibody and  one control blood with no 
antibody. A rough estimate of the mount of M  antigen produced by these 
strains as indicated by M precipitin tests is recorded by +  signs for each strain 
in the first coll~mu. Strain B930/24 with + + + +  M  antigen shows a strong 
(Jr++)  bactericidal reaction when tested with case 29 blood. It is negative 
with  the other  three  bloods.  Strain  D58X/ll  with  slightly less M  antigen 
(+++4-)  gives strong reactions with case 29 but is also good with case 32. 
Strain  C203/42,  still lower in the scale  according  to the precipitin  reaction, 
has a suggestion of reaction with case 3, as weU as good reactions with cases 
32 and 29. Finally Strain D121 with the lowest capacity to produce M antigen 
is the best indicator strain in all 3 positive cases. As shown in the preliminary 
tests in Tables IV a and IV b, this strain has sufficient growth in rotated tubes 
as compared with stationary so that it can be used in these bactericidal tests 
for specific antibody. 
It is apparent, therefore, that human sera which contain an excess of type- 
specific antibody can be successfully tested with strains  producing maximal 
mounts of M  antigen. In selecting  strains with an  intermediate  capacity to 
produce M  antigen in order to provide a more sensitive test organism for the 
low levels of antibody present in many human sera, the comparison of rotated 
and stationary sets of tubes, illustrated in Table IV a, is especially useful.  By 
this means the optimal proportion of M antigen to antibody can be assured for 
these sera of low titer. Occasionally  it may be necessary for best results to ex- 
amine the strain further by titrating it against serial  dilutions of homologous 
type rabbit antiserum to ensure its possession of enough M antigen for the test. 
Selection of a Type 28 Strain Suitable for Following the Rise and Fall of Anti- 
body in a Human Serum.--These tests were done with 2 of the Type 28 strains 
employed to study the rise and fall of antibody in a patient after a streptococcal 
infection.  Table VIa illustrates both of the biological tests described above to 
determine the relative amounts of M  antigen produced by these 2 strains. Al- 
though there is a difference between Strains T28/150A and B574 in their ability 
to grow in normal human blood in bactericidal tests, as indicated by the com- 
parison of rotated and stationary series, this difference is not great. When, bow- 
ever,  the 2 strains  are compared for ability to combine with  antibody, it is 
obvious that Strain B574, with less M antigen, would be a better assay strain 
than Strain T28/150A with its higher  content of M  antigen, which would re- 
quire more antibody to cause inhibition of growth. TABLE V 
Example of Optimal Proportions  of M  Antigen and Antibody Required for Demonstrating 
Minimal Antibody Levels in Human Sera 
Direct Bactericidal  Tests with Human Blood 
SWains  tested 
type 3 
~train B930/24 
~I antigen 
++++ 
X~/pe 3 
Strain D58X/ll 
M antigen 
+++4- 
Type 3 
Strain C203/42 
M  antigen 
++4- 
Type 3 
Strain D121 
M antigen 
++ 
Conditions of test* 
_=, 
No.  of  streptococci  inoc- 
ulated 
No. of streptococci  at end of 
test  with  whole  human 
blood from: 
Case 29 
"  32 
"  3 
"  10 
No.  of  streptococci  inoc- 
dated 
No. of streptococci  at end of 
test  with  whole  human 
blood from: 
Case 29 
"  32 
cc  ,3 
"  10 
No.  of  streptococci /noc- 
ulated 
No. of streptococd at  end 
of  test  with  whole  human 
blood  from: 
Case 29 
"  32 
"  3 
"  10 
No.  of  streptococci  inoc- 
ulated 
No. of streptococci  at end 
of  test  with  whole  human 
blood  from: 
Case 29 
"  32 
cc  3 
"  10 
Results of test 
No.  of colonies 
Inoculum 
Bactericidal  test 
16  8  1  0 
700  500  300 
=  oo  C  200 
oo  ~o  500  138 
Inoculum 
157  41  I  12  2 
I 
Bact~/ddal test 
14  0  0  0 
500  190  9  7 
co  ,0  C  261 
oo  ~o  C  700 
Inoculum 
131  26  [  16  l 
I 
Bactericidal  test 
7  0  0 
390  41  20 
,o  ,o  47 
,o  ,o  700 
f noculum 
25O  GO I  7 
I 
Bacteric/dal  test 
3  0  0 
98  0  0 
1000  0 
~o  500  32 
0 
0 
43 
0 
0 
0 
0 
43 
Antibody found 
+++  Type  3 
No  "  " 
+++4-  Type 3 
++  .... 
NO  ~¢  C¢ 
gg  ¢¢  ¢g 
+++.4-  Type 3 
+++  ,,  , 
]+++-4- Type 3 
!++4-  "  - 
]+  ,,  . 
No  "  " 
* For further details of tests, see Methods and Table II. 
See Table II for better reaction between Strain D121 and case 3. 
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Rise  and  Fall  of  Type-Specific  Antibody  in  Case  I0  Following  Untreated 
Pharyngitis with Strain B574,--The results of tests with these 2 strains, shown 
in Table VI b, substantiate the findings with regard to their properties. Case I0 
(see Table I c) acquired a laboratory infection  with StrainT28 before the M anti- 
TABLE VIa 
Detection of Minimal  Concentrations of Type-Specific Antibody in Human Serum Following 
Infection ugth Group A Streptococci of Known Type 
(a) Selection of strains suitable for testing. 
Direct and Indirect Bactericidal Tests 
Strains tested 
Type 28 
Strain T28/150A 
M antigen + +-b-b 
Type 28 
Strain B574 
M  antigen ++ 
Conditions  of test* 
No. of streptococci inoculated 
No. of streptococci at end of test with 
normal human blood and the follow- 
ing: 
(1)  Broth 
(a) Rotated tubes 
(b) Stationary tubes 
(2)  Type 28 anti-M serums 
diluted  1:1 
1:5 
1:25 
(3)  Normal rabbit serum~t 
diluted  1:1 
No. of streptococci inoculated 
No. of streptococci at end of test with 
normal human blood and the follow- 
ing: 
(1)  Broth 
(a) Rotated  tubes 
(b) Stationary tubes 
(2)  Type 28 anti-M serums 
diluted  1:1 
1:5 
1:25 
(3)  Normal rabbit serums 
diluted  1:1 
Results  of tests 
No. ofco~n~s 
lnoculum 
Bactericidal test 
2000  262 
2000  500 
31  26  41 
20  300  152 
700  161 
2000  500 
]noculgm 
Bactericidal test 
C  500 
C 
0  0 
8  0 
51  85  0 
2000  750 
112 
123 
0 
0 
118 
138 
74 
200 
230 
* For further details of tests, see Methods and 'rabies II, IV a, and IV b. 
Rotated  tubes. TABLE VI b 
Detection of Minimal Concentrations of Type-Specific Antibody in Human Serum Following 
Infection with Group A Streptococci of Known Type 
(b) Influence  of optimal proportions of M  antigen and antibody In demonstrating  rise and 
fall of circulating antibody. 
Bactericidal Tests witk the Blood of Case 10 Following Untreated Pharyngitis due to Type 28, 
Strain B574 
Date of 
serum or 
blood 
tested 
Results  with  varying culture  dilutions  of  several  Type 28 strains 
Strains  with  ++  M  antigen  Strains  with ++++  M  antigen 
No. of colonies  Strain  No.  No. of colonies 
'-'8--55  '0"  B574J  ~  C  438 
Control  29  "  124  [Date of infection 1-31-55] 
.,,  1 ,7,  67 
Control  30  "  190 
Control 
7-,8-56 
Control 
2  0 
2C  I 5~  200/  9~  I 
750  350  ,22  C 
C 2000~ 750 36{3 
C  4381  69 
500  70 
c  I  ,5912   2000  424 
6-18-57 
Control 
1-20-59 
Control 
1-20-59 
Control 
T28,/,63A 
T28~I31A 
T28~131A 
T28~I31A 
C 1000 140 
co  C 292 
"Bactericidal" anti- 
body found  and esti- 
mate of concentration 
None (preinfec- 
tion) 
First  suggestion-- 
3-2-35--Less 
evidence of anti- 
body with 
++++  M 
strain  than  with 
++  M strain 
C  500  0  13  First  convincing 
C 196  9  evidence,  10-27- 
55.  Maximum 
antibody  found 
10-27-55  to  4- 
17-56~ 
700  173  57  33[  Slight  decline  in 
C  700  titer  80 123 
oo 2000500 155  ++  M  strain still 
2000 500 216  gave  variable 
slightly  positive 
reactions  from 
1-18-57 to 10-2- 
58 
T28/131A  cCI 400267 
"  111 187 
No inhibition 
Trace of inhibition 
with  poorest  M 
strain 
Tests with bleedings at dates intermediate between those recorded  were consistent with the 
slope of the curve for those recorded  in the table. 
* Strain B574 from the throat of case 10 after accidental infection with Strain T28. 
For further accounts of the Type 28 strains used here, see also (8). 
On 10-27-55 several different Type 28 strains were all strongly inhibited by case I0 blood 
(see  "La," same individual, tests recorded  in Table III, reference 8). Most of these strains 
gave the same results as Strain B574 in later tests also. 
In retrospect,  early weak reactions prior to  10-27-55  (beginning about 3-2-55)  can be 
interpreted as being positive, as  well as some of the weaker reactions during the period of 
antibody decline.  These may be compared with some of the cases tested currently in wh/ch 
earlier bleedings were not available. 
For details of tests, see Methods and Table II. 
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gen  of  this  strain  was  enhanced  by  serial  mouse  passage  to  yield  Strain 
T28/150A with a higher content of M  antigen. Strain B574 was isolated from 
the throat culture of case 10.  Chemotherapy was not employed. Bactericidal 
tests with these two strains were carried out at frequent intervals. Although a 
suggestion of positive reaction was obtained with Strain B574 a month after the 
occurrence of the infection, it was 8 months before strong bactericidal reactions 
were observed even with this ++  M  strain (B574). Nor did the ++++  M 
strain, T28/150A, begin to show traces of inhibition with this individual's blood 
until a month later than the first reactions with Strain B574. Maximal reactions 
with both strains were obtained during the period 9 to 15 months after the in- 
fection,  followed by  a  more  rapid  decrease  in  the  phagocytosis-promoting 
properties of the serum with respect to Strain T28/150A than for the weaker 
M +  strain,  B574. 
These differences in effect of serum taken at different intervals following in- 
fection reflect the rise and fall in antibody level in the patient's blood. The re- 
suits are comparable to the differences shown in Table VIa which reflect differ- 
ences in relative concentrations of antigen and antibody demonstrated by serial 
dilution of rabbit  immune  serum. 
It  was  also  found  that  the  non-passage  strain,  T28,  was  comparable  to 
Strain B574 inits reactions both with rabbit antiserum and with case 10 serum. 
At the present time it would be questionable whether the weak reaction with 
Strain T28 could be considered evidence of antibody in this individual without 
the knowledge that this is the declining part of an antibody curve which has 
previously been unequivocally positive. 
It seems possible that weak reactions in some of the other cases with earlier 
known infections, in which the higher part of the curve is missing may, in fact, 
be representative of the same kind of situation. In some of these, a survey of 
other strains of the homologous type by the use of the tests described has led 
to the finding of assay strains suitable for establishing the presence of low con- 
centrations of antibody in these individuals tested many years after infection. 
DISCUSSION 
Type-specific antibodies in some individuals persist for as long as 32 years. 
The persistence, in contrast to the initiation (5, 7), of these antibodies could not 
be correlated directly with the severity of the streptococcal infection or with 
the serological type of the  causative  streptococcus. Neither  could  this per- 
sistence be explained on the basis that it was characteristic of the particular 
individual to produce large amounts of antibody, because in some instances 
the  same  individual had  had several infections of apparently equal severity 
with varying type-specific antibody response. 
Following  Group A  streptococcal infections, the appearance of circulating 
type-specific antibodies is delayed compared to the immune response to other R.  C.  LANCEFIELD  289 
streptococcal products, such as streptolysin-O (5, 7, 14). An example of the slow 
appearance  of type-specific antibody is given in Table VI b of this report. In 
the case cited the concentration of type-specific antibody did not reach a high 
level until 8 months after the occurrence of the streptococcal infection, although 
the antistreptolysin-O  peak was reached in 1 month and was declining within 
2 months. The significance of this delay in relation to immunity and to long- 
term persistence of type-specific antibodies is unknown. 
Evidence was obtained in a few instances by mouse protection tests that the 
type-specific antibodies for Group A streptococci in human sera are protective 
antibodies  and, therefore,  probably a  reliable indication of immunity. In the 
past the use of human sera for protection tests in mice against Group A strep- 
tococci has often given equivocal results  because the content of type-specific 
antibodies in the sera was not known. In this study by using sera in which the 
presence  of type-specific antibodies  had been  previously  determined,  it was 
possible  to  demonstrate some  protection,  although  the  antibody titer  was 
usually not high. Human sera with demonstrable  antibody for Types 3, 6, and 
13 protected mice against infection with streptococci of the homologous type 
to an extent roughly proportional  to the relative  concentration of antibody 
demonstrated by bactericidal tests. 
Although little definite proof is available, it seems unlikely that an individual 
with type-specific antibodies  would be susceptible  to infection with Group A 
streptococci of that type. Pertinent findings are those of the group who worked 
at the Streptococcal Disease Laboratory of the Armed Forces Epidemiological 
Board at Warren Air Force Base, Wyoming (13, 14). These investigators showed 
by means of bacteriostatic tests that the presence of type-specific antibodies 
did not seem to influence the transitory acquisition of streptococci of the same 
or of heterologous types. In these instances the transitory acquisition of strep- 
tococci was not associated  with antibody response. The persistence of organ- 
isms and the incidence of clinical and subclinical infections were, nevertheless, 
strikingly influenced by the presence of type-specific antibody but were un- 
affected by the presence of heterologous types of antibody. In their study the 
duration of these antibodies  was not established,  but it was thought probable 
that type-specific antibodies last for some years. 
The stimulus which causes antibodies to persist for many years is not known. 
Repeated subclinical  infections  would account for persistence  of antibodies, 
but the available evidence, such as the above, indicates that reinfections with 
with the same  serological type of Group  A streptococcus  rarely occur.  It is 
difficult  to  ascribe  the long-continued  occurrence  of type-specific antibodies 
against Group A streptococci  to the persistence  of the organism in some un- 
known location in the body, perhaps in unrecognizable form. In an individual 
such as case 30, it would be necessary to assume that he harbored at least 7 
different types of Group A streptococci. It is possible that streptococcal prod- 290  PERSISTENCE OF TYPE-SPECIFIC STREPTOCOCCAL ANTIBODIES 
ucts may remain in the tissues for long periods after the infecting  streptococci 
have been eliminated.  The extreme susceptibility of the type-specific iV[ antigen 
to proteolytic digestion,  however, would make it readily susceptible to destruc- 
tion in the body, and there is no evidence to indicate that any split products of 
the M  antigen retain antigenic specificity.  The simplest hypothesis is that the 
original  infection modifies  the antibody-producing cells permanently  so that 
they continue  to produce antibody (15).  If this  assumption is  correct,  then 
even individuals who have lost antibodies to a particular type would probably 
still  be immune  because  contact  with  the  original  antigen  would probably 
elicit  an  immediate  response. 
The  suppression  of  type-specific  antibody  formation  for  Group  A  strep- 
tococci by penicillin  or other chemotherapeutic drugs has been reported in a 
few studies (5, 7). It is possible that the current wide-spread use of penicillin 
will lead to the frequent occurrence  of reinfections  with the same serological 
type of Group A streptococci due to the absence of these antibodies, in contrast 
to the former rarity of such occurrences.  In the present series most of the pa- 
tients were untreated since their infections occurred before chemotherapeutic 
drugs were available. 
The selection  of suitable strains  of streptococci for testing human  sera is 
particularly important in bactericidal tests. Since their suitability depends on 
the amount of M  antigen produced by the streptococci (Tables V and VI b), 
the technique  developed for selection  of strains  also provides a  method for 
estimating the amount of M  protein contained in these organisms.  Two bio- 
logical  and  immunological  methods  are  suggested.  Both  are  only  roughly 
quantitative, but they are effective measures for the selection of strains capable 
of furnishing  the optimal proportions of 2¢i antigen for tests with sera of low 
antibody content. Comparison of ability of different strains of streptococci to 
resist phagocytosis and grow in normal human blood in rotated and stationary 
tubes is one of these methods (Table IV a). Further information may be ob- 
tained by a  comparison  of the amount of homologous type-specific antibody 
required to inhibit the growth of different strains in bactericidal tests (Tables 
IV b and VIa). Since quantitative methods for estimating iVI antigen contained 
in streptococci have previously been lacking, these biological assays have proved 
of use in the present bactericidal experiments,  and they are also  of value in 
certain  other  procedures  connected with  this  work.  For  example,  Group  A 
streptococci which  grow poorly in normal  human blood in rotated tubes as 
compared to stationary tubes because they lack IV[ antigen, are also avirulent 
for mice (9). One of the usual procedures for reestablishing  their ~vl production 
is to pass them serially  through mice. The acquisition of M  antigen and often 
of mouse virulence can be followed simply by testing these passage strains at 
intervals for growth in normal human blood in rotated and stationary tubes. 
Strains which grow equally well in the two sets of tubes have invariably pro- R.  C.  LANCE~FIELD  291 
duced maximal amounts of M antigen and are usually suitable antigens for pre- 
paring anti-M sera by immunization of rabbits or for use in virulence and pro- 
tection  experiments.  Thus  methods devised  for one  type of immunological 
assay have been useful for further elucidation of the properties of Group A 
streptococci. 
SUMMARY 
Whole blood or sera were collected from individuals who had had infections 
with Group A streptococci of known serological type as long ago as 10 to 32 
years.  Most  of  these  patients  had not been  treated with  chemotherapeutic 
drugs. By means of bactericidal tests with all these sera, and mouse protection 
tests  with  some,  type-specific antibodies could be  demonstrated in  at least 
half of them after a lapse of many years, the longest interval being 32 years. 
Two biological methods for estimating the amount of M antigen produced by 
Group A streptococci are described. By selecting strains for use by these meth- 
ods, optimal proportions of M  antigen and antibody could be employed in the 
tests and small amounts of antibody were, therefore, demonstrable. 
The assay methods for M  antigen are also of value for other experimental 
purposes. 
It is a pleasure to acknowledge the able  technical assistance  of Mr.  William N. Everly. 
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